Cutaneous microcystic lymphatic malformations (CMLMs) are rare conditions of children and adults resulting from abnormal embryologic development of lymphatic vessels. They present as clusters of vesicles full of lymph and blood of various extent. They ooze and bleed, inducing maceration, esthetic impairment, scars, pain, bacterial infections and impaired quality of life. Currently, treatments for CMLMs are disappointing, and their management is challenging. Sirolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine/threonine protein kinase involved in cell growth and proliferation, cellular metabolism, autophagy and angio-lymphangiogenesis. Topical sirolimus, known to be efficient and well tolerated in cutaneous angiofibromas linked to tuberous sclerosis, has recently been reported effective in few reports of patients with CMLMs. The objective of this trial is to compare the efficacy and safety of a 12-week application of 0.1% topical sirolimus versus topical vehicle in CMLMs in children and adults.
This blinded multicentre split body randomized controlled phase 2 trial aims to include 50 patients ≥ 6 years old who have a primary CMLM without an underlying malformation. The CMLM will be divided into 2 equal areas of the same severity that will be randomly allocated to 0.1% topical sirolimus or topical vehicle for 12 weeks. During the double-blind 12-week period, both topical products will be applied by a nurse to avoid inter-group contamination and for better compliance. At the end of the 12-week period, the patient/parent will treat the whole area of CMLM with 0.1% topical sirolimus on remaining lesions, for 8 more weeks. Patients will also be seen at week 20 (treatment will be stopped) and at month 12 to evaluate long-term efficacy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
55
The formulation is 0.03 g rapamycin, 1.5 g Transcutol, Quantum Satis (QS) 30g Excipial® hydrocream, corresponding to a concentration at 0.1%. The cream will be packaged in 30 ml aluminium tubes.
The same vehicle than the one used in the topical 0.1% sirolimus preparation will be used for the other half area of CMLM, i.e. Excipial® hydrocream. It will be packaged to maintain the double blind way of this trial and will be undistinguishable from the sirolimus cream.
ANGERS
Angers, France
BORDEAUX
Bordeaux, France
LYON AD
Bron, France
LYON PED
Bron, France
CAEN
Caen, France
DIJON
Dijon, France
Marseille
Marseille, France
Montpellier
Montpellier, France
NANTES
Nantes, France
NICE
Nice, France
...and 7 more locations
Efficacy of a 12-week application period of 0.1% topical sirolimus in cutaneous microcystic lymphatic malformation versus topical vehicle
PGA (Physician Global Assessment) score assessed by the investigator physician (blinded from the treatment). PGA score ranges from 0 (clear) to 5 (severe lesions), and is commonly used in several dermatologic conditions. For each patient, PGA of the area treated with the intervention (0.1% topical sirolimus) will be compared to PGA of the area treated with topical vehicle (inactive comparator)
Time frame: Week 12
Efficacy of 0.1% topical sirolimus in cutaneous microcystic lymphatic malformation versus topical vehicle
PGA (Physician Global Assessment) score assessed by the investigator physician (blinded from the treatment). PGA score ranges from 0 (clear) to 5 (severe lesions), and is commonly used in several dermatologic conditions. For each patient, PGA of the area treated with the intervention (0.1% topical sirolimus) will be compared to PGA of the area treated with topical vehicle (inactive comparator)
Time frame: Day 1, Week 6, Week 20, Month 12
Efficacy of 0.1% topical sirolimus vs vehicle regarding each of the following complications of the CMLM: oozing, bleeding, erythema, and thickness
Assessment by the investigator blinded to treatment with a visual analog scale (VAS) from 0 to 10 (0: no improvement, 10: recovery)
Time frame: Day 1, Week 12, Week 20, Month 12
Number of independent experts who correctly identify which area among both received the active treatment for each patient on the basis of standardised photographs
Standardized photographs will be performed at baseline and week 12: the experts will have to identify, at the end of the study, which area among both received the active treatment. In case of disagreement, a consensus will be reached between both experts; if consensus is not reached, a third expert will be sought for final decision. Interpretation by dermatologic experts (i.e correct identification of intervention/vehicle treated area) will be considered as correct or false, and the proportion of correct interpretation will be estimated. The proportion of correct interpretation will be compared to the theoretical 50% value, corresponding to a random assessment. Five photographs will be taken: 1) one of the patient including the malformation 2) one of the malformation (distance of 50 cm), 3) one of the malformation (distance of 15 cm), 4) profile photography and finally 5) three quarter view.
Time frame: Day1, Week 12
Global self-reported efficacy of topical sirolimus vs vehicle (with help of parents in case of children under 16 years)
Self-assessment of the global improvement of CMLM in both areas using a VAS (Visual Analog Scale) from 0 to 10 (0 no improvement and 10 recovery)
Time frame: Week 12, Week 20, Month 12
Functional and esthetic impairments (self-reported with help of parents in case of children under 16 years)
Using a VAS (Visual Analog Scale) from 0 to 10 (0 no improvement and 10 recovery)
Time frame: Day1, Week 20, Month 12
Pain linked to the CMLM (with help of parents in case of children under 16 years)
Using a VAS (Visual Analog Scale) from 0 to 10 (0 no pain and 10 worst imaginable pain)
Time frame: Day1, Week 20, Month 12
Effect on quality of life
Self-assessment of quality of life using the validated DLQI (Dermatology Life Quality Index) scale, or Child-DLQI for children (equal ou under 16 years old) from 0 to 30 (0 no impact on quality of life and 30 maximum impact on quality of life)
Time frame: Day 1, Week 20, Month 12
Evaluation of systemic passage of sirolimus by dosage of serum level of sirolimus
Dosage of serum level of sirolimus
Time frame: Week 6, Week 12, Week 20, +/- Week 16 (if CMLM ≥ 30*30 cm and/or ≥900 cm2)
Number of patients with biological adverse events and total number of biological adverse events (to assess the biological tolerance of topical sirolimus)
Number of patients with biological adverse events and total number of biological adverse events (blood samples at baseline, week 12 and week 20)
Time frame: Baseline, Week 12, Week 20
Number of patients with clinical adverse events and total number of clinical adverse events (to assess the clinical tolerance of topical sirolimus)
Number of patients with clinical adverse events and total number of clinical adverse events (record of local and general adverse events)
Time frame: Week 6, Week 12, Week 20
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.